Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus - Scorecard - MDSpire

Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus

  • By

  • Itai Danovitch

  • May 7, 2026

  • 0 min

Share

Clinical Scorecard: Managing Opioid Use Disorder in Hospitals During the Fentanyl Crisis—Expert Consensus Insights and Limitations

At a Glance

CategoryDetail
Condition
Key MechanismsFentanyl's high potency, unpredictable withdrawal trajectories, and the impact of emerging additives and adulterants complicate treatment.
Target Population
Care Setting

Key Highlights

  • Hospitalized patients often present with complex medical issues, including trauma, pain management, and psychiatric comorbidities, affecting OUD treatment.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Implement toxicology surveillance and public health advisories to monitor emerging contaminants, including local intelligence on prevalence.

      Risks

        Patient & Prescribing Data

        Hospitalized individuals with opioid use disorder, particularly those affected by fentanyl.

        Engagement with addiction consultation services improves post-discharge MOUD access.

        Clinical Best Practices

        • Adopt standardized protocols while ensuring individualized patient assessments and modifications based on clinical context.

        Related Resources & Content

        Original Source(s)

        Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus

        • by Itai Danovitch

        • May 7, 2026

        Related Content

        Prescribing Outside the Exam Room

        A DEA case exposes how controlled substances can move outside clinical oversight.

        Access to Medications for Opioid Use Disorder Among Veterans With Homeless Experience in Permanent Supportive

        FDA Monthly Preview: Key June Decisions to Watch

        Several FDA decisions across multiple specialties are expected this month.